Clinical Trial Update: Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity study of the meningococcal vaccine GSK134612 given with Priorix-Tetra in 12-23 month-olds; trial completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• GSK134612 (Meningococcal vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2017-12-15